Serum adiponectin, TNF-α, IL-12p70, and IL-13 levels in multiple sclerosis and the effects of different therapy regimens

NeuroImmunoModulation

Volumn 18, Issue 1, 2010, Pages 57-66

  Musabak, Ugur ^a   Demirkaya, Seref ^a   Genç, Gencer ^a   Ilikci, Rahsan Sagkan ^a   Odabasi, Zeki ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Adiponectin; Glatiramer acetate; Interferon; Interleukin; Multiple sclerosis; Pathogenesis

Indexed keywords

ADIPONECTIN; AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 12P70; INTERLEUKIN 13; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADIPONECTIN; ADULT; CYTOKINES; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-12; INTERLEUKIN-13; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955540342     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317393     Document Type: Article

References (45)

1. Sospedra M, Martin R: Immunology of mul-tiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
2. Dyment DA, Ebers GC, Sadovnick AD: Ge-netics of multiple sclerosis: Lancet Neurol 2004; 3:104-110.
3. Ozenci V, Kouwenhoven M, Huang YM, Kivisäkk P, Link H: Multiple sclerosis is as-sociated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)-and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000; 120:147-153.
4. Gran B, Rostami A: T cells, cytokines, and autoantigens in multiple sclerosis. Curr Neu-rol Neurosci Rep 2001; 1: 263-270.
5. Bielekova B, Martin R: Development of bio-markers in multiple sclerosis. Brain 2004; 127:1463-1478.
6. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R: Cytokine phe-notype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 1996; 45: 852-862. (Pubitemid 26332573)
7. Abbas AK, Lichtman AH: Cytokines; in Ab-bas AK, Lichtman AH (eds): Cellular and Molecular Immunology, ed 5, Philadelphia, Saunders, 2003, pp 243-274.
8. Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, Cutolo M, Tincani A, Todesco S: Th2 immune devia-tion induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol 2006; 22: 234-241.
9. Berg AH, Scherer PE: Adipose tissue, in-flammation, and cardiovascular disease. Circ Res 2005; 96:939-949.
10. Nedvídková J, Smitka K, Kopský V, Hainer V: Adiponectin, an adipocyte-derived pro-tein. Physiol Res 2005; 54: 133-140.
11. Kim HA, Choi GS, Jeon JY, Yoon JM, Sung JM, Suh CH: Leptin and ghrelin in Korean systemic lupus erythematosus. Lupus 2010; 19: 170-174.
12. Frisullo G, Angelucci F, Mirabella M, Cag-giula M, Patanella K, Nociti V, Tonali PA, Ba-tocchi AP: Leptin enhances the release of cy-tokines by peripheral blood mononuclear cells from relapsing multiple sclerosis pa-tients. J Clin Immunol 2004; 24:287-293.
13. Batocchi AP, Rotondi M, Caggiula M, Fri-sullo G, Odoardi F, Nociti V, Carella C, To-nali PA, Mirabella M: Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 2003; 139: 150-154.
14. Berilgen MS, Bulut S, Ustundag B, Tekatas A, Ayar A: Patients with multiple sclerosis have higher levels of serum ghrelin. Neuro Endo-crinol Lett 2005; 26: 819-822.
15. Hietaharju A, Kuusisto H, Nieminen R, Vuolteenaho K, Elovaara I, Moilanen E: El-evated cerebrospinal fluid adiponectin and adipsin levels in patients with multiple scle-rosis: a Finnish co-twin study. Eur J Neurol DOI: 10.1111/j.1468-1331.2009.02701.x.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for mul-tiple sclerosis: 2005 revisions to the 'McDon-ald Criteria. Ann Neurol 2005; 58: 840-846.
17. Drulovic J, Mostarica-Stojkovic M, Levic Z, Mesaros S, Stojsavljevic N, Popadic D, Pravica V: Serum interleukin-12 levels in patients with multiple sclerosis. Neurosci Lett 1998; 251:129-132.
18. Nicoletti F, Patti F, Cocuzza C, Zaccone P, Nicoletti A, Di Marco R, Reggio A: Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J NeuroImmunol 1996; 70:87-90.
19. Heesen C, Sieverding F, Schoser BG, Hadji B, Kunze K: Interleukin-12 is detectable in sera of patients with multiple sclerosis-associa-tion with chronic progressive disease course? Eur J Neurol 1999; 6: 591-596.
20. Soldan SS, Alvarez Retuerto AI, Sicotte NL, Voskuhl RR: Dysregulation of IL-10 and IL-12p40 in secondary progressive multiple sclerosis. J Neuroimmunol 2004; 146:209-215.
21. Ozenci V, Pashenkov M, Kouwenhoven M, Rinaldi L, Söderström M, Link H: IL-12/IL-12R system in multiple sclerosis. J NeuroImmunol 2001; 114: 242-252.
22. Hussien Y, Sanna A, Söderström M, Link H, Huang YM: Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in pa-tients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Mult Scler 2004; 10:16-25.
23. Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, Montella S, Buona-volontà L, Florio C, Postiglione L: Interleu-kin-10 and interleukin-12 modulation in pa-tients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non respond-ers. Immunopharmacol Immunotoxicol 2008; 30: 1-9.
24. Bartosik-Psujek H, Stelmasiak Z: The inter-leukin-10 levels as a potential indicator of positive response to interferon beta treat-ment of multiple sclerosis patients. Clin Neu-rol Neurosurg 2006; 108:644-647.
25. Carrá A, Onaha P, Sinay V, Alvarez F, Luetic G, Bettinelli R, San Pedro E, Rodríguez L: A retrospective, observational study compar-ing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol 2003; 10:671-676.
26. Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, Elias W, Obhof W, Viehöver A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdörfer C, QUASIMS Study Group: Quality Assessment in Multiple Scle-rosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-re-mitting multiple sclerosis. J Neurol 2007; 254: 67-77.
27. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon (INCOMIN) Trial Study Group: Every-oth-er-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359:1453-1460.
28. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B, EVIDENCE Study Group, Evidence of Interferon Dose-response: Euro-pean North American Comparative Effica-cy, University of British Columbia MS/MRI Research Group: Randomized, comparative study of interferon beta-1a treatment regi-mens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
29. Haas J, Firzlaff M: Twenty-four-month com-parison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neu-rol 2005; 12:425-431.
30. Nicoletti F, Marco RD, Patti F, Nicoletti A, Leonardi C, Reggio E, Meroni P, Reggio A: The antiinflammatory cytokine interleu-kin-13 is not detectable in the circulation of multiple sclerosis patients and is not in-ducible by interferon-beta1b treatment, that neither modifies its ex vivo secretion from peripheral blood mononuclear cells. Auto-immunity 2000; 32: 265-270.
31. Wiesemann E, Klatt J, Wenzel C, Heiden-reich F, Windhagen A: Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with mul-tiple sclerosis. Clin Exp Immunol 2003; 133: 454-460.
32. Ochi H, Osoegawa M, Wu XM, Minohara M, Horiuchi I, Murai H, Furuya H, Kira J: In-creased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 2002; 201:45-51.
33. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A: Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008; 128: 306-313.
34. Mei FJ, Osoegawa M, Ochi H, Minohara M, Nan S, Murai H, Ishizu T, Taniwaki T, Kira J: Long-term favorable response to interferon beta-1b is linked to cytokine deviation to-ward the Th2 and Tc2 sides in Japanese pa-tients with multiple sclerosis. J Neurol Sci 2006; 246: 71-77.
35. Jacobs LD, Cookfair DL, Rudick RA, Hern-don RM, Richert JR Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH: A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbat-ing-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Mult Scler 1995; 1:118-135
36. The IFNB Multiple Sclerosis Study Group: Interferon beta 1-b is effective in relapsing-remitting multiple sclerosis. I. Clinical re-sults of a multicenter, randomized, double blind, placebo-controlled trial. Neurology 1993; 43:655-661.
37. PRISMS (Prevention of Relapses and Dis-ability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Ran-domised double-blind placebo-controlled study of interferon beta-1a in relapsing/re-mitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
38. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB: Copolymer 1 reduces relapse rate and improves disability in re-lapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind pla-cebo-controlled trial. The Copolymer 1 Mul-tiple Sclerosis Study Group. Neurology 1995; 45:1268-1276.
39. Peter JB, Boctor FN, Tourtellotte WW: Se-rum and CSF levels of IL-2, sIL-2R TNF-al-pha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 1991; 41:121-123.
40. Maimone D, Gregory S, Arnason BG, Reder AT: Cytokine levels in the cerebrospinal flu-id and serum of patients with multiple scle-rosis. J Neuroimmunol 1991; 32:67-74.
41. Tsukada N, Miyagi K, Matsuda M, Yanagi-sawa N, Yone K: Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991; 104: 230-234.
42. Sharief MK, Thompson EJ: In vivo relation-ship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 1992; 38: 27-33.
43. Dong YX, Xu ZR, Lin PY: Association among serous and cerebrospinal fluid TNF-alpha level, gene polymorphisms of TNF-alpha and multiple sclerosis in Han nationality of southern China (in Chinese). Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 677-679.
44. Khurana SR, Bamer AM, Turner AP, Wadh-wani RV, Bowen JD, Leipertz SL, Haselkorn JK: The prevalence of overweight and obesity in veterans with multiple sclerosis. Am J Phys Med Rehabil 2009; 88:83-91.
45. Tomassini V, Pozzilli C: Sex hormones: a role in the control of multiple sclerosis? Expert Opin Pharmacother 2006; 7: 857-868.